Aspirin activation of eosinophils and mast cells: Implications in the pathogenesis of aspirin-exacerbated respiratory disease

Journal of Immunology

Volumn 193, Issue 1, 2014, Pages 41-47

  Steinke, John W ^a   Negri, Julie ^a   Liu, Lixia ^a   Payne, Spencer C ^a   Borish, Larry ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; EOSINOPHIL PROTEIN X; GAMMA INTERFERON; LYSINE; PROSTAGLANDIN D2; SALICYLATE SODIUM;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASPIRIN EXACERBATED RESPIRATORY DISEASE; BLOOD SAMPLING; CALCIUM TRANSPORT; CD34 SELECTION; CELL ACTIVATION; CELL DIFFERENTIATION; CELL MATURATION; CONTROLLED STUDY; DEGRANULATION; DISEASE ASSOCIATION; ENZYME ACTIVATION; ENZYME RELEASE; EOSINOPHIL; HUMAN; HUMAN CELL; MAST CELL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION;

ASPIRIN; ASTHMA, ASPIRIN-INDUCED; CALCIUM SIGNALING; CYCLOOXYGENASE INHIBITORS; CYSTEINE; EOSINOPHIL-DERIVED NEUROTOXIN; EOSINOPHILS; FEMALE; HUMANS; INTERFERON-GAMMA; LEUKOTRIENES; MALE; MAST CELLS; PROSTAGLANDIN D2;

EID: 84903596067     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1301753     Document Type: Article

References (39)

1. Steinke, J.W., S.C. Payne, and L. Borish. 2012. Interleukin-4 in the generation of the AERD phenotype: implications for molecular mechanisms driving therapeutic benefit of aspirin desensitization. J. Allergy. DOI: 10.1155/2012/182090.
2. Mascia, K., L. Borish, J. Patrie, J. Hunt, C. D. Phillips, and J. W. Steinke. 2005. Chronic hyperplastic eosinophilic sinusitis as a predictor of aspirin-exacerbated respiratory disease. Ann. Allergy Asthma Immunol. 94: 652-657.
3. Szczeklik, A., and D. D. Stevenson. 1999. Aspirin-induced asthma: advances in pathogenesis and management. J. Allergy Clin. Immunol. 104: 5-13.
4. Szczeklik, A., and E. Nizankowska. 2000. Clinical features and diagnosis of aspirin induced asthma. Thorax 55(Suppl 2): S42-S44.
5. Berges-Gimeno, M. P., R. A. Simon, and D. D. Stevenson. 2002. The natural history and clinical characteristics of aspirin-exacerbated respiratory disease. Ann. Allergy Asthma Immunol. 89: 474-478.
6. Sestini, P., L. Armetti, G. Gambaro, M. G. Pieroni, R. M. Refini, A. Sala, A. Vaghi, G. C. Folco, S. Bianco, and M. Robuschi. 1996. Inhaled PGE2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirinsensitive asthma. Am. J. Respir. Crit. Care Med. 153: 572-575.
7. Sladek, K., and A. Szczeklik. 1993. Cysteinyl leukotrienes overproduction and mast cell activation in aspirin-provoked bronchospasm in asthma. Eur. Respir. J. 6: 391-399.
8. Cowburn, A. S., K. Sladek, J. Soja, L. Adamek, E. Nizankowska, A. Szczeklik, B. K. Lam, J. F. Penrose, F. K. Austen, S. T. Holgate, and A. P. Sampson. 1998. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J. Clin. Invest. 101: 834-846.
9. Daffern, P. J., D. Muilenburg, T. E. Hugli, and D. D. Stevenson. 1999. Association of urinary leukotriene E4 excretion during aspirin challenges with severity of respiratory responses. J. Allergy Clin. Immunol. 104: 559-564.
10. Laidlaw, T. M., M. S. Kidder, N. Bhattacharyya, W. Xing, S. Shen, G. L. Milne, M. C. Castells, H. Chhay, and J. A. Boyce. 2012. Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by plateletadherent leukocytes. Blood 119: 3790-3798.
11. Dahlén, B., E. Nizankowska, A. Szczeklik, O. Zetterström, G. Bochenek, M. Kumlin, L. Mastalerz, G. Pinis, L. J. Swanson, T. I. Boodhoo, et al. 1998. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am. J. Respir. Crit. Care Med. 157: 1187-1194.
12. Kamil, A., O. Ghaffar, F. Lavigne, R. Taha, P. M. Renzi, and Q. Hamid. 1998. Comparison of inflammatory cell profile and Th2 cytokine expression in the ethmoid sinuses, maxillary sinuses, and turbinates of atopic subjects with chronic sinusitis. Otolaryngol. Head Neck Surg. 118: 804-809.
13. Payne, S. C., S. B. Early, P. Huyett, J. K. Han, L. Borish, and J.W. Steinke. 2011. Evidence for distinct histologic profile of nasal polyps with and without eosinophilia. Laryngoscope 121: 2262-2267.
14. Bachert, C., M. Wagenmann, U. Hauser, and C. Rudack. 1997. IL-5 synthesis is upregulated in human nasal polyp tissue. J. Allergy Clin. Immunol. 99: 837-842.
15. Pérez-Novo, C. A., J. B. Watelet, C. Claeys, P. Van Cauwenberge, and C. Bachert. 2005. Prostaglandin, leukotriene, and lipoxin balance in chronic rhinosinusitis with and without nasal polyposis. J. Allergy Clin. Immunol. 115: 1189-1196.
16. Fischer, A. R., M. A. Rosenberg, C. M. Lilly, J. C. Callery, P. Rubin, J. Cohn, M. V. White, Y. Igarashi, M. A. Kaliner, J. M. Drazen, and E. Israel. 1994. Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirinsensitive asthma. J. Allergy Clin. Immunol. 94: 1046-1056.
17. Steinke, J. W., L. Liu, P. Huyett, J. Negri, S. C. Payne, and L. Borish. 2013. Prominent role of interferon-g in aspirin-exacerbated respiratory disease. J. Allergy Clin. Immunol. 132: 856-865.e1-3.
18. Kim, Y. K., M. Uno, D. L. Hamilos, L. Beck, B. Bochner, R. P. Schleimer, and J. A. Denburg. 1999. Immunolocalization of CD34 in nasal polyposis. Effect of topical corticosteroids. Am. J. Respir. Cell Mol. Biol. 20: 388-397.
19. Denburg, J. A. 2000. Haemopoietic mechanisms in nasal polyposis and asthma. Thorax 55(Suppl 2): S24-S25.
20. Tegeder, I., J. Pfeilschifter, and G. Geisslinger. 2001. Cyclooxygenaseindependent actions of cyclooxygenase inhibitors. FASEB J. 15: 2057-2072.
21. Suzuki, Y., and C. Ra. 2009. Analysis of the mechanism for the development of allergic skin inflammation and the application for its treatment: aspirin modulation of IgE-dependent mast cell activation: role of aspirin-induced exacerbation of immediate allergy. J. Pharmacol. Sci. 110: 237-244.
22. Hudson, S. A., H. Herrmann, J. Du, P. Cox, el-B. Haddad, B. Butler, P. R. Crocker, S. J. Ackerman, P. Valent, and B. S. Bochner. 2011. Developmental, malignancy-related, and cross-species analysis of eosinophil, mast cell, and basophil siglec-8 expression. J. Clin. Immunol. 31: 1045-1053.
23. Kirshenbaum, A. S., J. P. Goff, T. Semere, B. Foster, L. M. Scott, and D. D. Metcalfe. 1999. Demonstration that human mast cells arise from a progenitor cell population that is CD34(+), c-kit(+), and expresses aminopeptidase N (CD13). Blood 94: 2333-2342.
24. Laidlaw, T. M., J. W. Steinke, A. M. Tinana, C. Feng, W. Xing, B. K. Lam, S. Paruchuri, J. A. Boyce, and L. Borish. 2011. Characterization of a novel human mast cell line that responds to stem cell factor and expresses functional FcepsilonRI. J. Allergy Clin. Immunol. 127: 815-822 e811-815.
25. White, A., T. Bigby, and D. Stevenson. 2006. Intranasal ketorolac challenge for the diagnosis of aspirin-exacerbated respiratory disease. Ann. Allergy Asthma Immunol. 97: 190-195.
26. Lee, R. U., A. A. White, D. Ding, A. B. Dursun, K. M. Woessner, R. A. Simon, and D. D. Stevenson. 2010. Use of intranasal ketorolac and modified oral aspirin challenge for desensitization of aspirin-exacerbated respiratory disease. Ann. Allergy Asthma Immunol. 105: 130-135.
27. Christie, P. E., P. Tagari, A. W. Ford-Hutchinson, S. Charlesson, P. Chee, J. P. Arm, and T. H. Lee. 1991. Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am. Rev. Respir. Dis. 143: 1025-1029.
28. Szczeklik, A., K. Sladek, R. Dworski, E. Nizankowska, J. Soja, J. Sheller, and J. Oates. 1996. Bronchial aspirin challenge causes specific eicosanoid response in aspirin-sensitive asthmatics. Am. J. Respir. Crit. Care Med. 154: 1608-1614.
29. Dahlén, B. 2000. Treatment of aspirin-intolerant asthma with antileukotrienes. Am. J. Respir. Crit. Care Med. 161: S137-S141.
30. Steinke, J. W., D. Bradley, P. Arango, C. D. Crouse, H. Frierson, S. E. Kountakis, M. Kraft, and L. Borish. 2003. Cysteinyl leukotriene expression in chronic hyperplastic sinusitis-nasal polyposis: importance to eosinophilia and asthma. J. Allergy Clin. Immunol. 111: 342-349.
31. Steinke, J. W. 2012. Editorial: yin-yang of EP receptor expression. J. Leukoc. Biol. 92: 1129-1131.
32. Kowalski, M. L., R. Pawliczak, J. Wozniak, K. Siuda, M. Poniatowska, J. Iwaszkiewicz, T. Kornatowski, and M. A. Kaliner. 2000. Differential metabolism of arachidonic acid in nasal polyp epithelial cells cultured from aspirinsensitive and aspirin-tolerant patients. Am. J. Respir. Crit. Care Med. 161: 391- 398.
33. Ying, S., Q. Meng, G. Scadding, A. Parikh, C. J. Corrigan, and T. H. Lee. 2006. Aspirin-sensitive rhinosinusitis is associated with reduced E-prostanoid 2 receptor expression on nasal mucosal inflammatory cells. J. Allergy Clin. Immunol. 117: 312-318.
34. Liu, T., T. M. Laidlaw, H. R. Katz, and J. A. Boyce. 2013. Prostaglandin E2 deficiency causes a phenotype of aspirin sensitivity that depends on platelets and cysteinyl leukotrienes. Proc. Natl. Acad. Sci. USA 110: 16987-16992.
35. Christie, P. E., C. M. Smith, and T. H. Lee. 1991. The potent and selective sulfidopeptide leukotriene antagonist, SK&F 104353, inhibits aspirin-induced asthma. Am. Rev. Respir. Dis. 144: 957-958.
36. Stevenson, D. D., A. J. Hougham, P. J. Schrank, M. B. Goldlust, and R. R. Wilson. 1990. Salsalate cross-sensitivity in aspirin-sensitive patients with asthma. J. Allergy Clin. Immunol. 86: 749-758.
37. Mathison, D. A., and D. D. Stevenson. 1979. Hypersensitivity to nonsteroidal antiinflammatory drugs: indications and methods for oral challenges. J. Allergy Clin. Immunol. 64: 669-674.
38. Higashi, N., M. Taniguchi, H. Mita, M. Osame, and K. Akiyama. 2002. A comparative study of eicosanoid concentrations in sputum and urine in patients with aspirin-intolerant asthma. Clin. Exp. Allergy 32: 1484-1490.
39. Bochenek, G., K. Nagraba, E. Nizankowska, and A. Szczeklik. 2003. A controlled study of 9alpha,11beta-PGF2 (a prostaglandin D2 metabolite) in plasma and urine of patients with bronchial asthma and healthy controls after aspirin challenge. J. Allergy Clin. Immunol. 111: 743-749.